ESMO 2023 | Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLC

Byoung Chul Cho, MD, PhD, Yonsei University, Seoul, Korea, discusses the Phase III MARIPOSA (NCT04487080) trial investigating the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a third-generation EGFR TKI, compared to osimertinib as a first-line treatment for EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). Among 1074 patients, amivantamab plus lazertinib demonstrated a 30% reduction in the risk of disease progression or death compared to osimertinib, with a median progression-free survival (PFS) of 23.7 months versus 16.6 months for osimertinib. The objective response rate (ORR) was 86% for amivantamab plus lazertinib versus 85% for osimertinib, and the duration of response (DoR) was longer with amivantamab plus lazertinib. Although overall survival (OS) data was interim, it showed a favorable trend for amivantamab plus lazertinib. Adverse events were generally manageable, and VTEs were more common with amivantamab plus lazertinib but mostly mild. MARIPOSA establishes amivantamab plus lazertinib as a new first-line standard of care for EGFR-mutated advanced NSCLC. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.